

[Open Peer Review on Qeios](#)

Inhibiting Efflux Pumps and Resistance Mechanisms: A Mini Review

Thualfakar Hayder Hasan Abusaiba¹, Ali Abdul Hussein¹, Taghreed F. Almahbob¹

¹ Jabir ibn Hayyan Medical University

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.

Abstract

Efflux pumps play a significant role in the development and spread of antibiotic resistance among bacteria. These specialized membrane proteins actively pump out various antibiotics and other toxic compounds, allowing bacteria to survive and thrive in the presence of these substances. Understanding the mechanisms by which efflux pumps contribute to antibiotic resistance is crucial for devising effective strategies to combat this global health threat. This article delves into the intricacies of efflux pump-mediated resistance, exploring the types and functions of efflux pumps, their role in antibiotic resistance, and the strategies employed to inhibit their activity. Additionally, it examines the challenges and future prospects in developing efflux pump inhibitors, highlighting case studies that showcase both successes and failures in this field. By shedding light on the inhibitory potential of efflux pumps, this article aims to contribute to the broader efforts in combating antibiotic resistance.

Thualfakar Hayder Hasan^{1,*}, Ali Abdul Hussein¹, Ahmed Abduljabbar Jaloob Aljanaby³

¹ *Jabir Ibn Hayyan Medical University, Iraq*

² *Department of Biology, University of Kufa, Faculty of Science, Najaf, Iraq*

*Corresponding author. Email: thualfakar.h.hasan@jmu.com

Keywords: Antibiotic resistance, Efflux Pumps, Bacteria.

1. Introduction to Efflux Pumps and Resistance Mechanisms

1.1. The Role of Efflux Pumps in Antibiotic Resistance

Antibiotic resistance is like that one friend who always knows how to dodge trouble. It's frustrating and, quite frankly, a little impressive^[1]. One of the sneaky ways bacteria develop resistance is through the use of efflux pumps, which are like tiny

molecular bouncers^[2]. These pumps are proteins located on the surface of bacterial cells, and their job is to pump out antibiotics and other harmful substances before they can do any damage^[3].

1.2. Types and Functions of Efflux Pumps

Efflux pumps come in different shapes, sizes, and flavors. Okay, maybe not flavors, but you get the point. There are several types of efflux pumps, each with its own specific function^[4]. Some pumps specialize in pumping out certain antibiotics, while others are more versatile and can kick out a variety of substances. It's like having a bouncer who can identify troublemakers based on their outfits. These pumps play a crucial role in bacterial survival and contribute to the development of antibiotic resistance. They're basically the MVPs of the resistance game^[5].

2. Understanding the Role of Efflux Pumps in Antibiotic Resistance

2.1. Mechanisms of Antibiotic Resistance

To understand efflux pumps, we need to dive into the world of antibiotic resistance. Picture this: you throw a wild party (the bacteria) and invite some unwelcome guests (the antibiotics). In a perfect world, the antibiotics would come in and ruin the party, knocking out all the bacteria^[6]. But in the world of resistance, the bacteria arm themselves with defenses to stay alive. One of those defenses is efflux pumps. These pumps actively pump out the antibiotics, rendering them ineffective and allowing the bacteria to keep the party going^[7].

2.2. Efflux Pumps as Defense Mechanisms

Efflux pumps are the bacterial equivalent of saying, "Not today, antibiotics!" They act as defense mechanisms, protecting the bacteria from the harmful effects of antibiotics^[8]. These pumps can be found not only in disease-causing bacteria but also in harmless bacteria that naturally reside in our bodies. It's like having a bouncer at the door of every bacteria-infested room, making sure nothing harmful gets in^[9]. Unfortunately, this defense mechanism can be a real headache when it comes to treating infections, as it reduces the effectiveness of antibiotics.

3. Mechanisms of Efflux Pump-Mediated Resistance

3.1. Active Efflux Systems and Their Organization

Efflux pumps are not just random proteins floating around in bacterial cells; they have their own organization^[10]. These pumps are part of active efflux systems, which consist of multiple proteins working together like a well-coordinated team. Think of it as a bacterial dance crew, with each member having a specific role^[11]. These systems are responsible for the assembly, regulation, and function of the efflux pumps. Understanding how these systems work can help researchers

come up with strategies to outsmart them^[12].

3.2. Substrate Specificity and Selectivity of Efflux Pumps

Efflux pumps may be picky eaters when it comes to pumping out substances. Just as some people have dietary restrictions, certain efflux pumps have substrate specificity^[13]. This means they can only pump out certain types of antibiotics or other substances. It's like being a bouncer who only lets in people wearing striped shirts. This selectivity is important to understand because it helps researchers develop targeted strategies to inhibit these pumps and restore the effectiveness of antibiotics^[14].

4. Inhibiting Efflux Pumps: Strategies and Approaches

4.1. Efflux Pump Inhibitors: An Overview

In the constant battle against antibiotic resistance, researchers have set their sights on tackling efflux pumps^[15]. One way to do this is by using efflux pump inhibitors (EPIs), which are like the bouncer's worst nightmare^[16]. These inhibitors interfere with the pumps' activity, preventing them from pumping out antibiotics. It's like sprinkling a little something in the bouncer's drink, making them unable to do their job effectively. By inhibiting the efflux pumps, the antibiotics can stay inside the bacterial cells and work their magic^[17].

4.2. Developing Small Molecule Inhibitors

To tackle efflux pumps, researchers are getting creative with tiny molecules. They're developing small molecule inhibitors that can bind to the pumps and block their pumping activity^[18]. It's like giving the bouncer a pair of handcuffs, making it impossible for them to kick anyone out. These small molecule inhibitors are designed to specifically target and inhibit the efflux pumps without interfering with other cellular processes. It's a precision strike against antibiotic resistance^[19].

4.3. Utilizing Natural Compounds as Efflux Pump Inhibitors

Nature always has a few tricks up its sleeve, and researchers are tapping into it to find potential efflux pump inhibitors. They're exploring natural compounds, like plant extracts and microbial products, to see if they can do the job. It's like using nature's own bouncer to take down the bacterial bouncers^[20]. These natural compounds may offer a more sustainable and environmentally friendly approach to inhibiting efflux pumps. Plus, it's always fun to see nature fight back against antibiotic resistance^[21].

So, the battle against antibiotic resistance continues, with efflux pumps being one of the tricky defenses bacteria use. By understanding how these pumps work and developing strategies to inhibit them, researchers are working to restore the effectiveness of antibiotics and keep those pesky bacteria in check. It's like winning a game of hide-and-seek against the sneaky bacteria^[22].

5. Overcoming Efflux Pump-Mediated Resistance in Clinical Settings

5.1. Combination Therapy: Targeting Efflux Pumps and Antibiotics

Combating antibiotic resistance is no easy task, but one promising approach is combination therapy^[23]. By targeting both efflux pumps and antibiotics simultaneously, we can enhance the effectiveness of existing drugs. Efflux pump inhibitors (EPIs) can be used in combination with antibiotics to prevent the pumps from expelling the drugs from the bacterial cells^[24]. This strategy has shown great potential in overcoming efflux pump-mediated resistance in various bacterial pathogens. Not only does it improve the efficacy of antibiotics, but it also helps to prolong the lifespan of existing drugs, reducing the need for newer, more potent antibiotics^[25].

5.2. Overcoming Efflux Pump-Mediated Resistance in Gram-Negative Bacteria

Efflux pump-mediated resistance is particularly problematic in gram-negative bacteria, as they possess complex efflux systems capable of expelling multiple classes of antibiotics^[26]. Overcoming this resistance mechanism in gram-negative bacteria requires the development of highly potent and specific EPIs. Researchers are actively exploring different strategies, such as screening natural compounds, designing synthetic molecules, and repurposing existing drugs, to tackle this challenge. Although progress has been made, further research is needed to identify effective inhibitors that can effectively combat efflux pump-mediated resistance in gram-negative bacteria^[27].

6. Challenges and Future Perspectives in Developing Efflux Pump Inhibitors

6.1. Identifying Novel Targets and Strategies

Developing effective efflux pump inhibitors is not without its challenges. One major hurdle is identifying novel targets and strategies to inhibit efflux pumps^[28]. Efflux systems are diverse and can vary between bacterial species, making it essential to understand the specific mechanisms involved in order to design targeted inhibitors^[29]. Moreover, finding compounds that selectively target efflux pumps without affecting essential bacterial processes is a daunting task. However, advancements in structural biology, high-throughput screening, and computational modeling are providing valuable insights, bringing us one step closer to identifying novel targets and strategies for efflux pump inhibition^{[14][30]}.

6.2. Overcoming Issues of Drug Toxicity and Resistance

Another challenge in developing efflux pump inhibitors is addressing issues of drug toxicity and resistance. EPIs should ideally have minimal toxicity to human cells while effectively inhibiting bacterial efflux pumps^[31]. Additionally, the risk of resistance emergence should be minimized to ensure long-term efficacy. By understanding the mechanisms of resistance

development and employing rational drug design approaches, scientists can develop inhibitors that are less prone to resistance and have improved safety profiles^[32]. This requires a comprehensive understanding of efflux pump biology and constant vigilance in monitoring resistance mechanisms^[33].

7. Case Studies: Successes and Failures in Inhibiting Efflux Pumps

7.1. Successful Efflux Pump Inhibition Strategies

Several success stories highlight the potential of inhibiting efflux pumps to overcome antibiotic resistance. One notable example is the use of a combination of the EPI verapamil with the antibiotic doxycycline against multi-drug-resistant *Staphylococcus aureus*^[34]. This combination demonstrated enhanced bacterial killing and improved treatment outcomes. Similarly, the EPI phenylalanine-arginine- β -naphthylamide (PA β N) has shown promising results in inhibiting efflux pumps in *Pseudomonas aeruginosa*. These success stories provide valuable insights and serve as inspiration for future research into efflux pump inhibition strategies^[35].

7.2. Challenges and Failures in Developing Efflux Pump Inhibitors

While there have been successes, there have also been challenges and failures in developing efflux pump inhibitors. Many potential EPIs that have shown promise in vitro fail to exhibit the same efficacy in complex biological systems or clinical trials^[36]. Some inhibitors may lack specificity or have unintended side effects that limit their clinical use. Additionally, the dynamic nature of efflux pump systems makes it challenging to predict the long-term effectiveness of inhibitors. These challenges highlight the need for continued research and refinement in the development of efflux pump inhibitors^[37].

8. Conclusion and Implications for Combating Antibiotic Resistance

8.1. The Importance of Targeting Efflux Pumps in Combating Resistance

Efflux pump-mediated resistance poses a significant threat to the effectiveness of antibiotics. By targeting these pumps, we can undermine a crucial mechanism of resistance and restore the efficacy of existing antibiotics. Efflux pump inhibitors, in combination with traditional antibiotics, offer a promising approach to combat resistance and extend the lifespan of available drugs. Efforts to identify novel targets, develop safe and specific inhibitors, and overcome challenges are crucial to effectively combat antibiotic resistance.

8.2. Future Directions and Implications for Clinical Practice

The development and utilization of efflux pump inhibitors have the potential to revolutionize clinical practice in the battle

against antibiotic resistance. As research progresses, it is essential to translate findings into clinical trials and ultimately into patient care. Additionally, the use of efflux pump inhibitors in combination with antibiotics should be further explored and optimized to maximize treatment outcomes. Efflux pump inhibition may also be utilized in other fields, such as agriculture, to mitigate the impact of resistance in non-clinical settings. By seizing these opportunities, we can overcome resistance and ensure the longevity of effective antibiotics for generations to come.

9. Conclusion and Implications for Combating Antibiotic Resistance

Efflux pumps pose a significant challenge in the battle against antibiotic resistance. This article has provided insights into the role of efflux pumps in antibiotic resistance mechanisms and explored various strategies to inhibit their activity. While there have been successes in developing efflux pump inhibitors, there are still challenges to overcome, such as drug toxicity and emerging resistance. However, targeting efflux pumps remains a promising approach to enhance the effectiveness of antibiotics and combat resistance. Continued research and innovation in this area are crucial to develop novel and effective therapies that can circumvent efflux pump-mediated resistance. By understanding and targeting efflux pumps, we can pave the way for a future where antibiotics remain effective tools in the fight against bacterial infections.

References

- ¹ ^Martinez-Gutierrez, F., Olive, P. L., Banuelos, A., Orrantia, E., Nino, N., & Sanchez, E. M. (2012). *Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine*, 8(3), 343-350.
- ² ^Elechiguerra, J. L., Burt, J. L., Morones, J. R., Camacho-Bragado, A., Gao, X., Lara, H. H., & Yacaman, M. J. (2005). *Interaction of silver nanoparticles with HIV-1. Journal of Nanobiotechnology*, 3(1), 6.
- ³ ^Raffi, M., Hussain, F., Bhatti, T. M., Akhter, J. I., Hameed, A., Hasan, M. M., & Shahzad, N. (2010). *Antibacterial characterization of silver nanoparticles against E. coli ATCC-15224. Journal of Materials Science and Technology*, 26(7), 663-670.
- ⁴ ^Lara, H. H., Ayala-Núñez, N. V., Ixtepan-Turrent, L., & Rodriguez-Padilla, C. (2010). *Mode of antiviral action of silver nanoparticles against HIV-1. Journal of Nanobiotechnology*, 8(1), 1-10.
- ⁵ ^Choi, O., Yu, C. P., Esteban Fernández, G., & Hu, Z. (2010). *Interactions of nanosilver with Escherichia coli cells in planktonic and biofilm cultures. Water Research*, 44(20), 6095-6103.
- ⁶ ^Kim, S. H., Lee, H. S., Ryu, D. S., Choi, S. J., & Lee, D. S. (2009). *Antibacterial activity of silver-nanoparticles against Staphylococcus aureus and Escherichia coli. Korean Journal of Microbiology and Biotechnology*, 37(1), 77-85.
- ⁷ ^Sondi, I., & Salopek-Sondi, B. (2004). *Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. Journal of Colloid and Interface Science*, 275(1), 177-182.
- ⁸ ^Li, W. R., Xie, X. B., Shi, Q. S., Duan, S. S., Ouyang, Y. S., Chen, Y. B., & Zhao, X. (2010). *Antibacterial effect of silver nanoparticles on Staphylococcus aureus. Biometals*, 24(1), 135-141.
- ⁹ ^Ruparelia, J., Chatterjee, A., Duttagupta, S., & Mukherji, S. (2008). *Strain specificity in antimicrobial activity of silver*

and copper nanoparticles. *Acta Biomaterialia*, 4(3), 707-716.

10. [^]Gurunathan, S., Han, J. W., Kwon, D. N., & Kim, J. H. (2014). Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria. *Nanoscale Research Letters*, 9(1), 1-17.
11. [^]Hasan TH, Alasedi KK, Aljanaby AA. A comparative study of prevalence antimicrobials resistance klebsiella pneumoniae among different pathogenic bacteria isolated from patients with urinary tract infection in Al-Najaf City, Iraq. *Latin American journal of pharmacy*. 2021 Apr 1;40:174-8.
12. [^]Al-Ethari AS, Hasan TH, Tikki KA, Bustani GS. Genotypic Detection of qnrA and qnrC Genes in *Citrobacter koseri* Isolated from Patients with Urinary Tract Infection. *Institut Razi. Archives*. 2022 Mar 1;77(2).
13. [^]Hasan, T.H., Kadhum, H.A., Al-Khilkhali, H.J.B. Epidemiology of VZV virus in Najaf Government, Iraq. *Latin American Journal of Pharmacy*, 2023, 42(Special Issue), pp. 188–190.
14. ^{a, b}Hassan, L.A., Darweesh, M.F., Hasan, T.H. The Immune-modulator Activity of *Pseudomonas aeruginosa* Extracted Protein: Azurin Charming Protein. *Latin American Journal of Pharmacy*, 2023, 42(Special Issue), pp. 245–251.
15. [^]Aljanaby AA, Al-Faham QM, Aljanaby IA, Hasan TH. Epidemiological study of mycobacterium tuberculosis in Baghdad governorate, Iraq. *Gene Reports*. 2022 Mar 1;26:101467.
16. [^]Hayder T and Aljanaby AAJ. Antibiotics susceptibility patterns of *Citrobacter freundii* isolated from patients with urinary tract infection in Al-Najaf governorate – Iraq. *Int.J.Pharm.Sci*. 2019a, 10(2): 1481-1488.
17. [^]Hayder T and Aljanaby AAJ. Genotypic characterization of antimicrobial resistance- associated genes in *citrobacter freundii* isolated from patients with urinary tract infection in Al-Najaf Governorate-Iraq. *OnLine Journal of Biological Sciences*, 2019 b, 19 (2): 132.145.
18. [^]Majeed, H.T., Hasan, T.H. and Aljanaby, A.A.J. Epidemiological study in women infected with toxoplasma gondii, rubella virus, and cytomegalo virus in Al-Najaf Governorate-Iraq. *International Journal of Pharmaceutical Research*, 2020;12, pp.1442-1447.
19. [^]Kadhum HA, Hasan TH. The Study of *Bacillus Subtilis* Antimicrobial Activity on Some of the Pathological Isolates. *International Journal of Drug Delivery Technology*, 2019 21;9(02):193-6.
20. [^]Hasan TH, Al-Harmoosh RA. Mechanisms of Antibiotics Resistance in Bacteria. *Sys Rev Pharm*. 2020, 11(6):817-23.
21. [^]Hasan TH, Extended Spectrum Beta Lactamase *E. Coli* isolated from UTI Patients in Najaf Province, Iraq. *International Journal of Pharmaceutical Research*. 2020, 12(4).
22. [^]Abdulla, Y.N., Aljanaby, A.J.I., Hasan, H.T., Aljanaby, A.J.A. Assessment of β -lactams and Carbapenems Antimicrobials Resistance in *Klebsiella Oxytoca* Isolated from Patients with Urinary Tract Infections in Najaf, Iraq. *Archives of Razi Institute*, 2022, 77(2), pp. 669–673.
23. [^]Li, W. R., Xie, X. B., Shi, Q. S., Zeng, H. Y., Ou-Yang, Y. S., Chen, Y. B., & Zhao, X. N. (2010). Antibacterial activity and mechanism of silver nanoparticles on *Escherichia coli*. *Applied Microbiology and Biotechnology*, 85(4), 1115-1122.
24. [^]Durán, N., Durán, M., de Jesus, M. B., Seabra, A. B., Fávaro, W. J., & Nakazato, G. (2016). Silver nanoparticles: a new view on mechanistic aspects on antimicrobial activity. *Nanomedicine: Nanotechnology, Biology and Medicine*, 12(3), 789-799.
25. [^]Sintubin, L., De Windt, W., Dick, J., Mast, J., van der Ha, D., Verstraete, W., & Boon, N. (2009). Lactic acid bacteria as reducing and capping agent for the fast and efficient production of silver nanoparticles. *Applied Microbiology and*

Biotechnology, 84(4), 741-749.

26. ^Feng, Q. L., Wu, J., Chen, G. Q., Cui, F. Z., Kim, T. N., & Kim, J. O. (2000). A mechanistic study of the antibacterial effect of silver ions on *Escherichia coli* and *Staphylococcus aureus*. *Journal of Biomedical Materials Research*, 52(4), 662-668.
27. ^Rai, M., Yadav, A., & Gade, A. (2009). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology Advances*, 27(1), 76-83.
28. ^Patra, J. K., Baek, K. H., & Green synthesis of metal nanoparticles using plants. *Green Chemistry*, 18(13), 3250-3266.
29. ^Amiri, M. S., & Ebrahimzadeh, M. A. (2018). Green synthesis, characterization, and antimicrobial activities of copper nanoparticles using *Achillea biebersteinii* flower extract. *Journal of Nanostructures*, 8(2), 136-143.
30. ^Rai, M., Ingle, A. P., Pandit, R., Paralikar, P., & Gupta, I. (2016). Copper nanoparticles: synthesis, characterization and their antibacterial activity. *Journal of Cluster Science*, 27(6), 1745-1756.
31. ^Krukiewicz, K., Zakrzewska, K., Wysokowski, M., Czaczyk, K., & Jesionowski, T. (2019). Copper nanoparticles as an active biocidal substance—Synthesis, antibacterial activity and cytotoxicity. *Materials Science and Engineering: C*, 105, 110041.
32. ^Raffi, M., Mehrwan, S., Bhatti, T. M., Akhter, J. I., Hameed, A., & Yawar, W. (2010). Investigations into the antibacterial behavior of copper nanoparticles against *Escherichia coli*. *Annals of Microbiology*, 60(1), 75-80.
33. ^Sirelkhatim, A., Mahmud, S., Seeni, A., Kaus, N. H., Ann, L. C., Bakhori, S. K. M., Hasan, H., Mohamad, D. (2015). Review on Zinc Oxide Nanoparticles: Antibacterial Activity and Toxicity Mechanism. *Nano-Micro Letters*, 7(3), 219-242.
34. ^Raza, A., Sime, F. B., Cabot, P. J., & Maqbool, F. (2019). Copper oxide nanoparticles induce toxicity in A549 cells via apoptosis and autophagy pathways. *Nanotoxicology*, 13(8), 1095-1115.
35. ^Bauer, R. A., & Wortzel, L. H.. Doctor's choice: The physician and his sources of information about drugs. *Journal of Marketing Research*, 1996, 3(1), 40-47.
36. ^Firoozeh F, Mahluji Z, Shams E, Khorshidi A, Zibaei M. New Delhi metallo-β-lactamase-1-producing *Klebsiella pneumoniae* isolates in hospitalized patients in Kashan, Iran. *Iranian journal of microbiology*. 2017 Oct;9(5):283.
37. ^Bina M, Pournajaf A, Mirkalantari S, Talebi M, Irajian G. Detection of the *Klebsiella pneumoniae* carbapenemase (KPC) in *K. pneumoniae* Isolated from the Clinical Samples by the Phenotypic and Genotypic Methods. *Iranian journal of pathology*. 2015;10(3):199.